Summary
- The World Health Organization has approved Bavarian Nordic’s mpox vaccine for adolescents aged 12 to 17 years
- This approval comes after the WHO declared mpox a global public health emergency due to a new virus strain
- The vaccine was previously approved for adults, making it easier for African countries to access
- Bavarian Nordic is planning clinical trials for children aged two to 12